JP2010534828A - スクリーニング、療法及び診断 - Google Patents

スクリーニング、療法及び診断 Download PDF

Info

Publication number
JP2010534828A
JP2010534828A JP2010517399A JP2010517399A JP2010534828A JP 2010534828 A JP2010534828 A JP 2010534828A JP 2010517399 A JP2010517399 A JP 2010517399A JP 2010517399 A JP2010517399 A JP 2010517399A JP 2010534828 A JP2010534828 A JP 2010534828A
Authority
JP
Japan
Prior art keywords
trem
ligand
receptor
sepsis
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2010517399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534828A5 (https=
Inventor
クオルオンナ マルクオ
クレスネイ−タイト ジェウリア
パニナ パオラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxell SpA filed Critical Bioxell SpA
Publication of JP2010534828A publication Critical patent/JP2010534828A/ja
Publication of JP2010534828A5 publication Critical patent/JP2010534828A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010517399A 2007-07-23 2008-07-23 スクリーニング、療法及び診断 Abandoned JP2010534828A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96161507P 2007-07-23 2007-07-23
PCT/EP2008/059668 WO2009013319A1 (en) 2007-07-23 2008-07-23 Screening, therapy and diagnosis

Publications (2)

Publication Number Publication Date
JP2010534828A true JP2010534828A (ja) 2010-11-11
JP2010534828A5 JP2010534828A5 (https=) 2011-09-01

Family

ID=39816994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010517399A Abandoned JP2010534828A (ja) 2007-07-23 2008-07-23 スクリーニング、療法及び診断

Country Status (5)

Country Link
US (1) US20100306863A1 (https=)
EP (1) EP2174131A1 (https=)
JP (1) JP2010534828A (https=)
CN (1) CN101821621A (https=)
WO (1) WO2009013319A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508763A (ja) * 2012-02-15 2015-03-23 ノヴォ ノルディスク アー／エス ペプチドグリカン認識タンパク質１に結合する抗体
JP2016527519A (ja) * 2013-08-09 2016-09-08 イノトレム 心血管疾患または心血管イベントを有するリスクを予測するための方法およびキット
WO2020179700A1 (ja) * 2019-03-01 2020-09-10 国立大学法人筑波大学 アレルギー疾患を処置することに用いるための組成物
JP2022540674A (ja) * 2019-07-15 2022-09-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｔｒｅｍ－１抗体およびその使用
US12617837B2 (en) 2019-03-01 2026-05-05 University Of Tsukuba Composition for use in treatment of allergic diseases

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8393201B2 (en) 2010-09-21 2013-03-12 Webtech Wireless Inc. Sensing ignition by voltage monitoring
RU2463606C1 (ru) * 2011-08-17 2012-10-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения Российской академии медицинских наук (УРАМН НИИ КПССЗ СО РАМН) Способ ранней диагностики осложненного системного воспалительного ответа у пациентов, оперированных в условиях искусственного кровообращения
CN102517287B (zh) * 2012-01-10 2013-09-11 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
AU2013311606B2 (en) 2012-09-07 2017-10-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) Trem-Like Transcript 1 (TLT-1) and uses thereof
ES2950399T3 (es) * 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
CA3091047A1 (en) * 2018-02-14 2019-08-22 Yale University Compositions for modulation of a trem or treml protein and methods of use
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111157741B (zh) * 2019-12-30 2022-08-16 广州市妇女儿童医疗中心 髓系细胞触发受体1在制备胃炎诊断或治疗试剂中的应用及试剂盒
CN112526143B (zh) * 2020-12-03 2021-08-03 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
CN113687081A (zh) * 2021-05-19 2021-11-23 大汉生物科技(广东)有限公司 髓系细胞触发受体2在制备脓毒症相关功能产品中的应用
EP4388136A4 (en) * 2021-08-17 2025-07-23 Biomeme Inc METHODS FOR CHARACTERIZING INFECTIONS AND METHODS FOR DEVELOPING CORRESPONDING TESTS
CN114736957B (zh) * 2022-04-15 2024-03-12 中国人民解放军空军军医大学 外泌体介导rna casc15干预阿尔茨海默症突触损失的应用
CN116908446B (zh) * 2023-06-27 2024-05-07 广州市妇女儿童医疗中心 用于诊断川崎病冠状动脉瘤的生物标志物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
IT1164225B (it) * 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5413923A (en) * 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
PT1024191E (pt) * 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
GB0305478D0 (en) * 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508763A (ja) * 2012-02-15 2015-03-23 ノヴォ ノルディスク アー／エス ペプチドグリカン認識タンパク質１に結合する抗体
JP2016527519A (ja) * 2013-08-09 2016-09-08 イノトレム 心血管疾患または心血管イベントを有するリスクを予測するための方法およびキット
WO2020179700A1 (ja) * 2019-03-01 2020-09-10 国立大学法人筑波大学 アレルギー疾患を処置することに用いるための組成物
JPWO2020179700A1 (https=) * 2019-03-01 2020-09-10
JP7546924B2 (ja) 2019-03-01 2024-09-09 国立大学法人 筑波大学 アレルギー疾患を処置することに用いるための組成物
US12617837B2 (en) 2019-03-01 2026-05-05 University Of Tsukuba Composition for use in treatment of allergic diseases
JP2022540674A (ja) * 2019-07-15 2022-09-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｔｒｅｍ－１抗体およびその使用
JP7796005B2 (ja) 2019-07-15 2026-01-08 ブリストル－マイヤーズ スクイブ カンパニー 抗ｔｒｅｍ－１抗体およびその使用

Also Published As

Publication number Publication date
CN101821621A (zh) 2010-09-01
US20100306863A1 (en) 2010-12-02
WO2009013319A1 (en) 2009-01-29
EP2174131A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
JP2010534828A (ja) スクリーニング、療法及び診断
EP1817337B1 (en) Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis
CA2342376C (en) A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20160251434A1 (en) Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
KR20060089732A (ko) Ｔｉｍ-3 리간드 및 그의 방법
O'Shea et al. Exit of the pre-TCR from the ER/cis-Golgi is necessary for signaling differentiation, proliferation, and allelic exclusion in immature thymocytes
US7534571B2 (en) Diagnostic and prognostic compounds and method
JP2008522162A (ja) Ｍｅｒの診断用および治療用の作用薬
AU2005234705B2 (en) Therapeutic peptides and method
US20060263770A1 (en) Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
JP6555687B2 (ja) 免疫制御剤
Stappers et al. Recognition of DHN-melanin by MelLec, is required for protective immunity to Aspergillus
EP2722342A1 (en) Methods and compositions for the treatment of pancreatic cancer
US20190263906A1 (en) Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
KR101268562B1 (ko) Ｔｌｔ-6 단백질에 대한 항체 및 그 응용
CA2715100C (en) A novel receptor trem(triggering receptor expressed on myeloid cells) and uses thereof
BRPI0616438A2 (pt) proteÍna, polinucleotÍdeo, anticorpo contra uma proteÍna secretora ou de membrana, ou um fragmento funcional do mesmo, hibridoma, agente terapÊutico para uma doenÇa autoimune, agente para inibir adesço de cÉlulas t, e, mÉtodo para triar uma substÂncia
Gupta et al. Dendritic cell lectin receptors (dectin-2 receptors family)
JP2004173531A (ja) 免疫受容体タンパク質
Niederlová Role of Bardet-Biedl syndrome (BBS) protein complex in T cells
King On the Immunological Roles of TLT2 and HSH2
Cunningham et al. Workshop 2: Neuroendocrine tumors: Genetics, tumor biology and treatment
BARTZ et al. Workshop K Innate Immunity
BAUMANN et al. R. 1 FcyRI, FcyRIII and CSaR are co-dominant in the initiation of the inflam-matory cascade
Bonecchi Identification of new molecules involved in dendritic cell localization

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110711

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20120403